| scholarly article | Q13442814 |
| P50 | author | Donal MacGrogan | Q57052717 |
| Lap Ho | Q60418097 | ||
| Jun Wang | Q60419678 | ||
| Giulio Maria Pasinetti | Q16734229 | ||
| P2093 | author name string | Dale J Lange | |
| Zhong Zhao | |||
| Nelson Humala | |||
| Andrei Voustianiouk | |||
| Meenakshisundaram Thiyagarajan | |||
| Jason Suh | |||
| P2860 | cites work | Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. | Q45280649 |
| Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis | Q48357472 | ||
| Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. | Q51714635 | ||
| Mitochondria and the pathogenesis of ALS | Q73929279 | ||
| Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis | Q73929287 | ||
| Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis | Q74481406 | ||
| CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations | Q74625760 | ||
| Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis | Q28131805 | ||
| Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria | Q28270155 | ||
| Amyotrophic lateral sclerosis | Q29619516 | ||
| Mitochondria in sporadic amyotrophic lateral sclerosis | Q30472587 | ||
| Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease | Q34015557 | ||
| Mitochondrial degeneration in amyotrophic lateral sclerosis. | Q34551000 | ||
| Amyotrophic lateral sclerosis: a review of current concepts. | Q35226371 | ||
| The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism | Q35652475 | ||
| D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease | Q35919815 | ||
| Insulin, ketone bodies, and mitochondrial energy transduction. | Q36706028 | ||
| D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease | Q36976707 | ||
| Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase | Q37357532 | ||
| Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients | Q43883813 | ||
| A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis | Q44315290 | ||
| Altered vulnerability to kainate excitotoxicity of transgenic-Cu/Zn SOD1 neurones | Q45147182 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| P304 | page(s) | 29 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | BMC Neuroscience | Q15766477 |
| P1476 | title | A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis | |
| P478 | volume | 7 |
| Q57742321 | A Ketogenic Diet Improves Mitochondrial Biogenesis and Bioenergetics via the PGC1α-SIRT3-UCP2 Axis |
| Q42275985 | A ketogenic diet accelerates neurodegeneration in mice with induced mitochondrial DNA toxicity in the forebrain |
| Q35023971 | A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of Huntington's disease |
| Q41990257 | A ketogenic diet may offer neuroprotection in glaucoma and mitochondrial diseases of the optic nerve |
| Q37594297 | A plural role for lipids in motor neuron diseases: energy, signaling and structure |
| Q38103571 | ALS Untangled No. 20: the Deanna protocol |
| Q57357838 | ALSUntangled 15: Coconut Oil |
| Q38552413 | AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis |
| Q39014987 | Alternative Fuels in Epilepsy and Amyotrophic Lateral Sclerosis. |
| Q64229457 | Anti-Neuroinflammatory Effect of Jaeumganghwa-Tang in an Animal Model of Amyotrophic Lateral Sclerosis |
| Q58113183 | Antioxidants prevent inflammation and preserve the optic projection and visual function in experimental neurotrauma |
| Q41475139 | Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders |
| Q34353543 | Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets |
| Q44276835 | Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients |
| Q34187004 | Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis |
| Q38295414 | Calpain inhibition protected spinal cord motoneurons against 1-methyl-4-phenylpyridinium ion and rotenone |
| Q34474226 | Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease |
| Q33802454 | Cerebral metabolic adaptation and ketone metabolism after brain injury. |
| Q36299228 | Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis |
| Q35956389 | Comorbidities in Neurology: Is adenosine the common link? |
| Q26777929 | Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis |
| Q34217599 | D-beta-hydroxybutyrate extends lifespan in C. elegans |
| Q34023773 | D-β-hydroxybutyrate is protective in mouse models of Huntington's disease |
| Q51093485 | D-β-hydroxybutyrate promotes functional recovery and relieves pain hypersensitivity in mice with spinal cord injury. |
| Q36804600 | Dietary therapies for epilepsy and other neurological disorders: highlights of the 3rd international symposium |
| Q33972116 | Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy |
| Q59794101 | Disease-modifying effects of metabolic perturbations in ALS/FTLD |
| Q36012034 | Dysregulated expression of death, stress and mitochondrion related genes in the sciatic nerve of presymptomatic SOD1(G93A) mouse model of Amyotrophic Lateral Sclerosis |
| Q38366741 | Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis |
| Q36549674 | Effects of exogenous ketone supplementation on blood ketone, glucose, triglyceride, and lipoprotein levels in Sprague-Dawley rats |
| Q52651163 | Energy metabolism in ALS: an underappreciated opportunity? |
| Q90460659 | Exogenous Ketones Lower Blood Glucose Level in Rested and Exercised Rodent Models |
| Q90531525 | Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions |
| Q33523281 | Gene expression in a Drosophila model of mitochondrial disease. |
| Q35086167 | Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions |
| Q42377167 | Genetic induction of hypometabolism by ablation of MC4R does not suppress ALS-like phenotypes in the G93A mutant SOD1 mouse model. |
| Q34074537 | Genetically altering organismal metabolism by leptin-deficiency benefits a mouse model of amyotrophic lateral sclerosis |
| Q38105917 | High-fat and ketogenic diets in amyotrophic lateral sclerosis |
| Q49620553 | How Can a Ketogenic Diet Improve Motor Function? |
| Q39109418 | Hyperbaric Environment: Oxygen and Cellular Damage versus Protection |
| Q21262020 | Hypometabolism as a therapeutic target in Alzheimer's disease |
| Q39123661 | Induction of apoptosis by antimycin A in differentiated PC12 cell line |
| Q28483194 | Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis |
| Q38936285 | Ketogenic Diet and Cancer-a Perspective |
| Q92570178 | Ketogenic Diet in Alzheimer's Disease |
| Q22299266 | Ketogenic Diets: An Update for Child Neurologists |
| Q34766019 | Ketogenic diet improves core symptoms of autism in BTBR mice |
| Q30448973 | Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology |
| Q21284703 | Ketogenic diet in neuromuscular and neurodegenerative diseases |
| Q34432306 | Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism |
| Q36196765 | Ketogenic diets, mitochondria, and neurological diseases |
| Q34509699 | Ketogenic diets: from cancer to mitochondrial diseases and beyond. |
| Q34795761 | Ketone bodies as a therapeutic for Alzheimer's disease |
| Q34252732 | Ketone bodies as signaling metabolites. |
| Q37978003 | Ketone bodies in epilepsy |
| Q45824470 | Ketone-Based Metabolic Therapy: Is Increased NAD+ a Primary Mechanism? |
| Q42177440 | Ketones prevent synaptic dysfunction induced by mitochondrial respiratory complex inhibitors |
| Q38958585 | Management and therapeutic perspectives in amyotrophic lateral sclerosis |
| Q55237897 | Medium-Chain Fatty Acids, Beta-Hydroxybutyric Acid and Genetic Modulation of the Carnitine Shuttle Are Protective in a Drosophila Model of ALS Based on TDP-43. |
| Q39101800 | Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments |
| Q39251141 | Metabolic Vulnerability in the Neurodegenerative Disease Glaucoma |
| Q42370957 | Metabolic control of vesicular glutamate transport and release. |
| Q42749841 | Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model |
| Q89043356 | Metabolism and epilepsy: Ketogenic diets as a homeostatic link |
| Q33294971 | Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. |
| Q38745984 | Neuroketotherapeutics: A modern review of a century-old therapy |
| Q49334640 | Neuronal Lipid Metabolism: Multiple Pathways Driving Functional Outcomes in Health and Disease. |
| Q34280603 | Neuroprotection by acetoacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat--possible involvement of kynurenic acid |
| Q36752235 | Neuroprotection in diet-induced ketotic rat brain after focal ischemia |
| Q37923014 | Neuroprotection in metabolism-based therapy |
| Q43120302 | Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP-induced neurotoxicity |
| Q33783000 | New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders |
| Q58126926 | Non-invasive assessment of disease progression and neuroprotective effects of dietary coconut oil supplementation in the ALS SOD1 mouse model: A H-magnetic resonance spectroscopic study |
| Q27023108 | Novel mitochondrial targets for neuroprotection |
| Q33936763 | One universal common endpoint in mouse models of amyotrophic lateral sclerosis |
| Q35239387 | PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43. |
| Q96303127 | Potential Preventive Strategies for Amyotrophic Lateral Sclerosis |
| Q64885218 | Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention. |
| Q35624347 | Purines and neuronal excitability: links to the ketogenic diet |
| Q59340690 | Reduced AMPK activation and increased HCAR activation drive anti-inflammatory response and neuroprotection in glaucoma |
| Q37093737 | Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease |
| Q61817166 | Role of Ketogenic Diets in Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease) |
| Q38257960 | Role of energy metabolic deficits and oxidative stress in excitotoxic spinal motor neuron degeneration in vivo |
| Q64987886 | Satiating Effect of a Ketogenic Diet and Its Impact on Muscle Improvement and Oxidation State in Multiple Sclerosis Patients. |
| Q56936883 | Structural and Functional Rescue of Chronic Metabolically Stressed Optic Nerves through Respiration |
| Q21245063 | Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial |
| Q47886328 | Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma |
| Q37710385 | The Current Status of the Ketogenic Diet in Psychiatry |
| Q64119649 | The effect of ketogenic diet on behaviors and synaptic functions of naive mice |
| Q33954540 | The effects of the ketogenic diet on behavior and cognition |
| Q38577066 | The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis. |
| Q21129287 | The ketogenic diet as a treatment paradigm for diverse neurological disorders |
| Q37861273 | The ketogenic diet for Dravet syndrome and other epileptic encephalopathies: an Italian consensus. |
| Q34174680 | The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma |
| Q24617926 | The ketogenic diet: uses in epilepsy and other neurologic illnesses |
| Q35852049 | The nervous system and metabolic dysregulation: emerging evidence converges on ketogenic diet therapy |
| Q24681728 | The neuropharmacology of the ketogenic diet |
| Q24646616 | The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies |
| Q93014731 | Therapeutic alternative of the ketogenic Mediterranean diet to improve mitochondrial activity in Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review |
| Q36114275 | Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis |
| Q92775462 | Uses for humanised mouse models in precision medicine for neurodegenerative disease |
| Q24644968 | Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis |
| Q39003451 | β-Hydroxybutyrate in the Brain: One Molecule, Multiple Mechanisms |
| Q28299317 | Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric |
Search more.